TORONTO

多伦多

,

，

May 21, 2026

2026年5月21日

/PRNewswire/ - Synakis Corp., a Toronto-based biotechnology company developing ocular therapies for retinal disease and glaucoma, announced today the close of an oversubscribed CAD $2.6 million pre-seed financing round to advance SNK-125, its vitreous replacement therapy for retinal detachment.

/PRNewswire/ - 总部位于多伦多的生物技术公司Synakis Corp.致力于开发视网膜疾病和青光眼的眼部疗法，今天宣布完成了超额认购的260万加元的预种子轮融资，以推进其用于视网膜脱离的玻璃体替代疗法SNK-125。

Proceeds will support completion of GLP toxicology studies by early 2027 for an Investigational Testing Authorization (ITA) filing with Health Canada, and lead optimization for ocular therapeutic delivery.

收益将用于支持在2027年初之前完成GLP毒理学研究，以向加拿大卫生部提交研究性测试授权（ITA）申请，并优化眼部治疗递送的先导化合物。

The financing round was co-led by Toronto Innovation Acceleration Partners (TIAP) and Chiefswood Private Capital Inc., with additional investment from the Ontario Centre of Innovation (OCI) through the Life Sciences Innovation Fund (LSIF), and from the Canadian Glycomics Network (GlycoNet) through the Kickstart Program..

本轮融资由多伦多创新加速合作伙伴（TIAP）和Chiefswood私人资本公司共同领投，安大略创新中心（OCI）通过生命科学创新基金（LSIF）以及加拿大糖组学网络（GlycoNet）通过Kickstart计划提供了额外投资。

Prakash Gowd, Interim President and CEO of TIAP, said, 'TIAP's investment reflects our mission of transforming Canadian health science innovation into successful commercial ventures and supporting high-potential startups.'

TIAP临时总裁兼首席执行官普拉卡什·高德表示：“TIAP的投资体现了我们将加拿大健康科学创新转化为成功的商业项目并支持高潜力初创企业的使命。”

Jake Krembil, Vice-President of Chiefswood, added, 'After following Synakis for years, we remain impressed by the rigor of its science and platform.'

杰克·克雷姆比尔，齐斯伍德副总裁补充说：“在关注Synakis多年后，我们仍然对其科学和平台的严谨性印象深刻。”

Synakis' proprietary hydrogel platform was designed for safe ocular delivery and enables vitreous replacement and sustained therapeutic delivery. SNK-125 is intended to eliminate blurry vision and face-down posturing associated with existing gas and oil treatments for retinal detachment. Independent validation reinforces the potential of Synakis' hydrogel in retinal therapeutics..

Synakis的专有水凝胶平台旨在实现安全的眼部递送，并能够进行玻璃体替代和持续的治疗递送。SNK-125旨在消除与现有视网膜脱离气体和油类治疗相关的视力模糊和面部朝下的姿势。独立验证进一步证实了Synakis水凝胶在视网膜治疗中的潜力。

Molly Shoichet, Synakis' CSO and Co-Founder, said, 'The company is excited to advance technologies aimed at preserving vision.'

莫莉·肖伊奇特，赛纳基斯的首席科学官兼联合创始人表示：“公司对于推进旨在保护视力的技术感到兴奋。”

Dr. Rob Devenyi, vitreoretinal surgeon and Synakis' CMO and Co-Founder, noted 'the need for improved patient solutions given the limitations of current retinal detachment treatments.'

德文尼博士（Dr. Rob Devenyi），玻璃体视网膜外科医生以及Synakis的首席医疗官和联合创始人，指出“鉴于当前视网膜脱离治疗的局限性，需要改进患者解决方案。”

Thierry Nivaggioli, Synakis' CEO, said, 'This financing, together with independent validation, reinforces both the strength of our science and the unmet need for improved retinal therapies.'

Synakis公司首席执行官蒂埃里·尼瓦格里表示：“此次融资以及独立验证进一步证明了我们的科学实力，也证实了改进视网膜治疗手段的迫切需求。”

About Synakis

关于Synakis

Synakis is a Toronto-based pre-clinical biotechnology company developing ocular products to preserve vision through its proprietary platform technology. The company is developing products for retinal diseases, retinal detachment, and glaucoma. Synakis was spun out of the laboratory of Professor Molly Shoichet at the University of Toronto.

Synakis是一家位于多伦多的临床前生物技术公司，通过其专有平台技术开发眼部产品以保护视力。该公司正在开发用于视网膜疾病、视网膜脱离和青光眼的产品。Synakis源自多伦多大学Molly Shoichet教授的实验室。

For more information, visit .

欲了解更多信息，请访问 。

www.synakis.ca

www.synakis.ca

.

。

About TIAP

关于TIAP

TIAP supports commercialization of therapeutic, medical device, and digital health/AI innovations from Toronto research institutions and has helped launch more than 70 companies that have raised over $1 billion in private investment.

TIAP 支持多伦多研究机构的治疗、医疗器械和数字健康/人工智能创新的商业化，并帮助成立了70多家公司，这些公司已筹集了超过10亿美元的私人投资。

About Chiefswood

关于奇弗斯伍德

Chiefswood Private Capital is a Canadian family office investment firm dedicated to supporting Canadian startups with patient, long-term capital.

齐夫斯伍德私人资本是一家加拿大家族办公室投资公司，致力于用耐心的长期资本支持加拿大初创企业。

SOURCE Synakis

源 Synakis

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示